We have unique, proven capabilities with autologous fibroblast cells—the most common cell in skin and connective tissue. Using this proprietary technology offers us significant opportunities to develop cell and gene therapies that target the underlying cause of debilitating rare skin and connective tissue diseases.”
— John Maslowski, Senior Vice President, Scientific Affairs